studyId: syn51133946 studyName: DHART SPORE Project 3 - A High Content Clinical Trial (ADVL1521) of the MEK Inhibitor Trametinib in Juvenile Myelomonocytic Leukemia (JMML), a Phase II clinical trial initiative: DHART-SPORE Project 3 fundingAgency: NIH-NCI